Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.
Scotland boosts bio-based manufacturing with �75m fund
Biotech companies in Scotland�s thriving bio-based manufacturing have been invited to apply for up to �1m funding within the Launchpad programme.
BioInnovation Institute Boosts Six Life Science Companies
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BIIs Venture House programme.
Majority of EU agri-council supports NGT deregulation
At a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.
New detection method for protein degraders
German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
??Study: New breeding methods hardly contribute to climate protection
According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.
CEPI commits up to US$80m to University of Oxford to develop vaccines
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.
Pairwise and Bayer collaborate to CRISPR short-stem maize
Bayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System.
Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.
Mithra raises 20m through private placement
Women’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise 20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice Capital.